Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Dettman · SciRah

Researcher profile · Semantic Scholar

E. Dettman

Share profile

E. Dettman — researcher profile on SciRah

h-index: 8
Works: 34
Citations: 952

Most-cited papers

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
S. Lonial, Hans C. Lee, A. Badros, S. Trudel +34 more
2019The Lancet Oncology664 citations
Semantic Scholar
Targeting Calcium Signaling To Induce Epigenetic Reactivation of Tumor Suppressor Genes in Cancer
N. J. Raynal, Justin T. Lee, You-Jun Wang, Annie Beaudry +17 more
2015Cancer Research96 citations Open access
Semantic Scholar
Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors
E. Dettman, S. Simko, Bernard A Ayanga, Brandi L Carofino +3 more
2011Oncogene58 citations Open access
Semantic Scholar
Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
J. Ishizawa, K. Kojima, T. McQueen, V. Ruvolo +9 more
2015PLoS ONE26 citations Open access
Semantic Scholar
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
B. Carter, P. Mak, H. Mu, Xiang-Meng Wang +7 more
2019Haematologica25 citations Open access
Semantic Scholar
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.
C. Rudin, H. R. Kim, A. Navarro, M. Gottfried +16 more
2023Journal of Clinical Oncology16 citations Open access
Semantic Scholar
DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).
S. Usmani, E. Terpos, W. Janowski, H. Quach +6 more
202015 citations
Semantic Scholar
An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function.
B. D. Smith, S. Warner, Clifford J. Whatcott, Adam Siddiqui-Jain +6 more
201511 citations
Semantic Scholar
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
M. Ponz-Sarvisé, S. Rha, C. Gomez-Roca, Laura Ortega Morán +16 more
2026Cancer Research Communications7 citations Open access
Semantic Scholar
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
J. Bar, Emilio Esteban, D. Rodríguez-Abreu, S. Aix +19 more
2024Lung Cancer6 citations Open access
Semantic Scholar
Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159
E. Dettman, F. Rigat, J. Albert, R. Barnard +7 more
2018Blood6 citations Open access
Semantic Scholar
Abstract 3400: Mitochondrial profiling in AML patients treated with an Alvocidib containing regimen reveals MCL1 dependency in responder bone marrow
E. Dettman, S. Warner, Camille E. Doykan, Melissa Arn +4 more
20156 citations
Semantic Scholar
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.
Martin Reck, Ki Hyeong Lee, N. Frost, V. Breder +12 more
2024Journal of Clinical Oncology4 citations
Semantic Scholar
Abstract 380: Discovery of new epigenetic drugs among FDA-approved drug libraries
N. J. Raynal, Justin T. Lee, You-Jun Wang, J. Garriga +15 more
20144 citations
Semantic Scholar
22O Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study
C. le Tourneau, C. Rojas, A. Leary, K. Yonemori +16 more
2024ESMO Open2 citations Open access
Semantic Scholar
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.
Cai Chen, E. Dettman, Wei Zhou, Alexander Gozman +6 more
2024Future Oncology2 citations Open access
Semantic Scholar
Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors
C. Shao, Yi-Xin Ren, Heng Zhou, Cai Chen +6 more
2023JCO Precision Oncology2 citations
Semantic Scholar
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).
Evan Y. Yu, Se Hoon Park, Jeffrey C. Goh, S. Shin +16 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study
Changxia Shao, Yi-Xin Ren, Heng Zhou, Liam C. Lee +6 more
2024Advances in Therapy1 citations
Semantic Scholar
Prevalence and prognosis of BRCAm, homologous recombination repair mutation (HRRm) or HR deficiency positive (HRD+) across tumor types.
C. Shao, Yi-Xin Ren, Heng Zhou, Cai Chen +5 more
2022Journal of Clinical Oncology1 citations
Semantic Scholar
Real-world effectiveness of pembrolizumab among patients with TMB-H advanced solid tumors.
Wenjun Zhong, Xinyue Liu, Lei Zhang, R. Groisberg +6 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).
Martin Gutierrez, Wei-Sen Lam, A. Schoenfeld, M. Gubens +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
P2.085: HER3 and HER2 in a Real-World Cohort of Danish Patients With Metastatic Non-Small Cell Lung Cancer
K. Zu, P. Meldgaard, E. Dettman, B. Zhao +1 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors
Wen-Jun Zhong, E. Dettman, Lei Zhang, Alexander Gozman +7 more
2026Pediatric Hematology & Oncology0 citations
Semantic Scholar
2789P Real-world molecular epidemiology study of select biomarkers in extensive-stage small-cell lung cancer (ES-SCLC)
C. Rudin, C. Gay, N. Choudhury, A.-C. Chiang +7 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
Prevalence of androgen receptor ligand-binding domain mutations (AR-LBDm) in circulating tumor DNA (ctDNA) versus tissue biopsies in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) and other tumor types.
E. Antonarakis, A. Bernard-Tessier, Cai Chen, A. Vajdi +7 more
2025Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract 1015: Real-world evaluation of androgen receptor (AR) ligand-binding domain (LBD) mutations in Chinese patients with metastatic castration-resistant prostate cancer (mCRPC)
Yufei Chen, B. Dong, Da-Peng Li, Ying Xiao +4 more
2025Cancer Research0 citations
Semantic Scholar
Prevalence of Homologous Recombination Repair Mutations and Association with Clinical Outcomes in Patients with Solid Tumors: A Study Using the AACR Project GENIE Dataset
Changxia Shao, Heng Zhou, Cai Chen, E. Dettman +4 more
2025Cancers0 citations Open access
Semantic Scholar
Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.
E. Felip, S. Ponce Aix, J. Bar, Emilio Esteban +16 more
2024Journal of Clinical Oncology0 citations
Semantic Scholar
908P Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
S. Seo, B. Calderon, H.-H. Chou, C-H. Hsu +16 more
2024Annals of Oncology0 citations Open access
Semantic Scholar
Prevalence and prognosis of hypoxia‐inducible factor‐2α (HIF‐2α) pathway gene mutations across advanced solid tumors
Wen-Jun Zhong, Jiemin Ma, Cai Chen, E. Dettman +4 more
2024Cancer Medicine0 citations Open access
Semantic Scholar
Abstract CT216: Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial
J. Bar, E. Esteban, D. Rodríguez-Abreu, S. Aix +18 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 2282: Decitabine response in FLT3-negative AML is associated with mitochondrial priming
E. Dettman, Camille E. Doykan, J. Ishizawa, Weiguo Zhang +6 more
20160 citations
Semantic Scholar
Abstract P4-01-10: Predictive impact of circulating tumor cells with an epithelial-to-mesenchymal transition phenotype in patients with primary breast cancer treated with primary systemic therapy
Fanny Le Du, D. Duose, E. Dettman, J. A. Summer +8 more
20150 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Cristescu×11
Invite
R. Cristescu — researcher profile on SciRah
Cai Chen×8
Invite
Cai Chen — researcher profile on SciRah
Alexander Gozman×7
Invite
Alexander Gozman — researcher profile on SciRah
Fan Jin×6
Invite
Fan Jin — researcher profile on SciRah

×5

Invite

M. Cardone — researcher profile on SciRah

Invite

J. Kobie — researcher profile on SciRah

Invite

Yi-Xin Ren — researcher profile on SciRah

Invite

Heng Zhou — researcher profile on SciRah

Changxia Shao×5

Invite

Changxia Shao — researcher profile on SciRah

Invite

T. Csőszi — researcher profile on SciRah

D. Rodríguez-Abreu×4

Invite

D. Rodríguez-Abreu — researcher profile on SciRah

Invite

E. Felip — researcher profile on SciRah